Zoetis (ZTS)
(Delayed Data from NYSE)
$170.37 USD
-4.90 (-2.80%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $170.37 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$170.37 USD
-4.90 (-2.80%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $170.37 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View
by Zacks Equity Research
Zoetis (ZTS) exceeds both earnings and sales expectations in the first quarter of 2018.
Zoetis (ZTS) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Zoetis surpassed earnings and sales estimates in the first quarter of 2018.
Zoetis (ZTS) Up 7.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bear of the Day: Endo International (ENDP)
by Madeleine Johnson
Litigation has hit this opioid drug maker hard. Is there any chance for a rebound?
M&A, Innovation & New Drugs to Drive Pharma Stocks
by Zacks Equity Research
The new tax law, which cuts the corporate tax rate from 35% to 21% and encourages companies to bring back cash held overseas at a one-time tax rate of 10%, is expected to spur merger activity.
The Zacks Analyst Blog Highlights: Texas Instruments, Statoil, Comcast, Zoetis and HP
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Texas Instruments, Statoil, Comcast, Zoetis and HP
Top Stock Reports for Texas Instruments, Statoil & Comcast
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments (TXN), Statoil (STO) and Comcast (CMCSA).
Zoetis (ZTS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Zoetis surpassed earnings and sales estimates in the fourth quarter of 2017.
Teva Completes Sale of Women's Health Segment for $703M
by Zacks Equity Research
Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.
5 Stocks You Can't Afford to Ignore
by David Bartosiak
These five stocks are breaking out to new highs as earnings estimates continue to come in to the upside.
Zacks.com featured highlights include: Tempur Sealy, MSCI, Zoetis, Darden Restaurants and Illinois Tool Works
by Zacks Equity Research
Zacks.com featured highlights include: Tempur Sealy, MSCI, Zoetis, Darden Restaurants and Illinois Tool Works
Top Stock Reports for Apple, Facebook & MetLife
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Facebook (FB) and MetLife (MET).
Zoetis (ZTS) Q3 Earnings & Sales Beat Estimate; 2017 View Up
by Zacks Equity Research
Zoetis (ZTS) announced third quarter results with earnings and sales both beating estimates.
Top Stock Reports for Cisco, Enterprise Products Partners & Prudential
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Enterprise Products Partners (EPD), and Prudential (PRU).
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.
Zoetis (ZTS) Q2 Earnings In-line, Sales Beat; 2017 View Up
by Zacks Equity Research
Zoetis (ZTS) reported an in-line earnings per share while revenues beat estimates in the second quarter 2017.
Should You Buy Zoetis (ZTS) Ahead of Earnings?
by Zacks Equity Research
Zoetis (ZTS) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Is Zoetis (ZTS) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Zoetis, Inc. (ZTS) is expected to focus on performance of companion animal business during its second-quarter results.
Adamas Provides Positive Long-term Data on Parkinson's Drug
by Zacks Equity Research
Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.
Zoetis (ZTS) Up 6.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet
by Zacks Equity Research
Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.
Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data
by Zacks Equity Research
Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study
Horizon (HZNP) Sells European Rights for Procysbi & Quinsair
by Zacks Equity Research
Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.
Roche's Arthritis Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
by Zacks Equity Research
Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.